Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow | Main | The Neuro Revolution in China Progressing »

April 29, 2010

Speakers for Neurotech 2010 - Boston, May 19-20

Email This Entry

Posted by Zack Lynch

350_conference-banner-2010-350.jpgWe've been heads down putting together an amazing conference this year. Visit the Neurotech 2010 conference website to see full schedule. Here are this year's speakers:

Andrew Firlik General Partner, Foundation Medical Partners; Stephen Knight, Managing Partner, Fidelity Biosciences; Art Pappas, Managing Partner, Pappas Ventures; Liam Ratcliffe, Venture Partner, New Leaf Venture Partners; Casey Lynch, Managing Director, NeuroInsights -- Ulf Ljungberg, CEO, NeuroNova; Brad Margus, President & CEO, Envoy Therapeutics; Will Rosellini, CEO, MicroTransponder Inc.; Jim Schoeneck, President & CEO, BrainCells, Inc., Ellen Baron, Partner, Oxford Bioscience Partners -- Mike Detke, Chief Medical Officer, MedAvante; Jamie Heywood Co-founder, Chairman, PatientsLikeMe; Remy Luthringer, CEO, Forenap Pharma; Suzan Onel Partner, K&L Gates; Joyce Cramer, President, Epilepsy Therapy Project -- Greg Stock, CEO, Signum Biosciences; Konrad Glund, CEO, Probiodrug; Michael Pierschbacher, CEO, American Life Science Pharmaceuticals; Shawn Lyndon. CEO, Orasi Medical; Dan O'Connell, Managing Partner, NeuroVentures Capital -- Chris Fibiger Chief Scientific Officer, Biovail; Marianne De Backer, VP Business Development, Johnson & Johnson; Guy Seabrook, Sr. Director, Neuroscience Global External Research & Development, Eli Lilly; Ravi Kiron,Managing Director, Adjuvant Global Advisors -- Christopher deCharms, CEO, Omneuron; Alex Doman, CEO, Advanced Brain Technologies, Tom Dusenberry, CEO, Dusenberry Entertainment; Revere Greist Founder, Waypoint Health Innovations; A.K. Pradeep, CEO, NeuroFocus, Roger Quy General Partner, Technology Partners -- Shafique Virani, Director CNS Business Development, Roche; Lothar Krinke, SVP, Research and Development, Medtronic; Leslie Coney; Sr. Director of Business Development, Biogen Idec; Doug Carlson Sr. Director, US Business Development, Lundbeck A/S; Christine de Los Reyes,Managing Partner, Biotech Partnering Solutions; Jim Broderick, President, SetPoint Medical; Ed Boyden, Assistant Professor, MIT Media Lab; Ben Matteo, CEO, Eos Neuroscience; Marcelo Lima, President and CEO, ImThera Medical, -- Derek Small, COO & Acting CEO, Naurex, Bob Linke, President & CEO, Embera NeuroTherapeutics; Andreas Neef, Fellow, Bernstein Focus Neurotechnology; Walter Greenleaf President & CEO, InWorld Solutions; Manuel Lopez-Figueroa, Vice President, Bay City Capital -- Amy Kruse Executive Director, Neuroscience Division, Total Immersion Software, Kaleb McDowell, Soldier Performance Division, Neuroscience Strategic Research Initiative, Cognition & Neuroergonomics - Collaborative Alliance Manager, Army Research Laboratory; Dylan Schmorrow, Office of the Secretary of Defense, Assistant Director, Human Systems, Roy Stripling, Head Human Performance Training & Education, Office of Naval Research, Chris Forsythe, Distinguished Member of Technical Staff, Sandia National Laboratories -- Ronald Burch CEO, Cerephex, Stephen Collins, President and CEO, NeuroTherapeutics Pharma; Bruce McCarthy,CEO, Afferent Pharmaceuticals; Linda Watkins, Founder, Xalud Therapeutics; Heath Lukatch, Partner, Novo Ventures Bruce Bean, Harvard; Gabriela Chiosis, Sloan Kettering Cancer Center; Miles Cunningham, McLean Hospital; Hagit Eldar-Finkelman, Tel Aviv University; Ana Lukic, Predictek; Mike Vitek, Cognosci, Junying Yuan, Harvard; Jill Heemskerk, Program Director, Office of Translational Research, NINDS/NIH

If you are in neurotech, you should probably be here. Register

Comments (0) + TrackBacks (0) | Category: NIO


POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)





Remember me?


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20
Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
McGovern Institue for Brain Research at MIT Goes Web 2.0
The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
Neuropharma FDA Approvals Down in 2009
Tel Aviv Neurotech Cluster Thrives